Meeting the Big Shots | Academician Wang Hongyang and Delegation Visit Maxin Company for Exchange and Guidance
Editor’s Note:
Suddenly, warm winds arrive, following the arrival of Minor Heat. On July 9th, Professor Wang Hongyang, an academician of the Chinese Academy of Engineering and Director of the National Center for Liver Cancer Science, along with her team, visited Maxin Company for guidance. Wang Xiaoya, General Manager of Maxin Company, and relevant leaders from functional departments accompanied the visit and participated in the exchange symposium.
Figure 1. Academician Wang Hongyang’s team and the Maxin team engaged in discussion and exchange.
General Manager Wang Xiaoya first introduced the basic situation and development history of Maxin Company, including its corporate structure, R&D platforms, product line composition, market applications, and industrialization status. She provided an in-depth analysis of core technologies such as independent monoclonal antibody development and instrument automation, reported on the progress of key projects and R&D achievements in recent years, and also raised issues faced by the pathology discipline and domestic enterprises under the current background of precision medicine. She expressed hope for both sides to focus on practical matters and strengthen cooperation.
After listening to the report, Academician Wang and her team highly praised the achievements Maxin has made so far. They engaged in in-depth discussions on current industry hotspots and future development directions, and provided valuable opinions and suggestions regarding the cultivation of Maxin’s landmark project outcomes. Academician Wang stated that there is vast room and potential for the development of domestic precision medicine, strongly agreeing that “precise diagnosis precedes precise medicine.” She noted the significant shortage of pathology diagnostic talents and the substantial application and expansion space for new technologies, whether in histological immunohistochemistry or next-generation sequencing, circulating tumor cells, and digital pathology. Domestic pathology enterprises still have much to accomplish. Drawing from her own team’s experience, the academician also shared the achievements her team has made and their experience in talent echelon construction, emphasizing that only by focusing on basic big data research and platform construction can domestic enterprises truly achieve leadership.
Figure 2. Academician Wang Hongyang and Maxin’s Technical Director Yang Qinghai deeply discuss the IHC staining performance of liver cancer biomarkers (First from left: Dr. Tan Yexiong from the Eastern Hepatobiliary Surgery Institute; Second from left: Academician Wang Hongyang)
As early as 2012, Academician Wang Hongyang’s team and Maxin reached a cooperation consensus on the liver cancer biomarker Glypican-3 diagnostic kit. This visit and exchange activity will inject vitality into the in-depth cooperation between the two sides in the field of liver cancer. It is anticipated that both parties will achieve more results in exploring diagnostic models more suitable for Chinese liver cancer patients, bringing more benefits to Chinese liver cancer patients.
Introduction to Academician Wang Hongyang
Professor Wang Hongyang, female, is an expert in oncology and molecular biology. She is an academician of the Chinese Academy of Engineering, a fellow of The World Academy of Sciences (TWAS), a Changjiang Distinguished Professor of the Ministry of Education, a chief physician, a doctoral supervisor, and a recipient of the National Science Fund for Distinguished Young Scholars. She currently serves as the Director of the National Center for Liver Cancer Science and the Director of the International Cooperation Research Center for Biological Signal Transduction. She also holds concurrent positions as Vice Chairman of the Chinese Anti-Cancer Association, Chairman of the Precision Medicine Professional Committee of the Chinese Medical Doctor Association, and Vice President of the Shanghai Medical Association.
She has long been engaged in basic and clinical research on tumors, making significant contributions to the inflammation-cancer transformation of tumors, signal network regulation, and the development of liver cancer diagnostic reagents.She has published over 200 SCI papers in influential mainstream international journals.In the past five years, she has applied for 30 invention patents, with 14 granted (including 2 international patents). The Glypican-3 liver cancer diagnostic reagent she led in developing received approval for clinical application from the former China Food and Drug Administration (CFDA) (it is the first liver cancer diagnostic kit in China with completely independent intellectual property rights to receive approval).She has successively presided over more than ten major and key national and provincial-level scientific and technological research projects.As the first completer, she has received 9 awards, including the inaugural National Science and Technology Progress Award (Innovation Team), the Second Prize of the National Natural Science Award, the First Prize of the Shanghai Natural Science Award, and the First Prize of the Shanghai Medical Science and Technology Award.
Visit Highlights
Figure 3. Academician Wang Hongyang and her team visit the Maxin exhibition hall.
Figure 4. Academician Wang Hongyang carefully learns about Maxin’s development history.
Figure 5. Academician Wang Hongyang’s team visits the Maxin laboratory.